AIRS vs NVO
AIRS: AirSculpt operates a proprietary, minimally invasive body contouring platform that removes fat and tightens skin through 31 treatment centers, competing with traditional liposuction and non-surgical fat reduction while benefiting from rising GLP-1 drug adoption. NVO: A global leader in diabetes and obesity care, pioneering breakthrough GLP-1 receptor agonist therapies for chronic disease management.
Side-by-side fundamentals
| Metric | AIRS | NVO | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $4.96 | $44.28 | |
| Market cap as of 2026-08-05 | $350M | $206.5B | |
| P/E as of 2026-08-05 | n/a | 10.99 | |
| PEG as of 2026-08-05 | n/a | 16.16 | |
| Net margin as of 2026-08-05 | -7.4% | +37.2% | NVO higher |
| Gross margin as of 2026-08-05 | +66.1% | +81.8% | NVO higher |
| Operating margin as of 2026-08-05 | -7.8% | +45.3% | NVO higher |
| ROE as of 2026-08-05 | -12.4% | +66.4% | NVO higher |
| ROA as of 2026-08-05 | -5.9% | +23.3% | NVO higher |
| Debt / equity as of 2026-08-05 | 0.45 | 0.72 | AIRS lower |
| Revenue growth (YoY) as of 2026-08-05 | -11.8% | +8.1% | NVO higher |
| Revenue CAGR (3y) SEC XBRL | -3.5% | +20.4% | NVO higher |
| Dividend yield as of 2026-08-05 | n/a | +3.8% | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-08-05 | 2.40 | 1.84 | |
| 1-year return as of 2026-08-04 close | -17.7% | -9.3% | NVO higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.